624736-64-7Relevant academic research and scientific papers
Process development of CP-481715, a novel CCR1 antagonist
Li, Bryan,Andresen, Brian,Brown, Matthew F.,Buzon, Richard A.,Chiu, Charles K.-F.,Couturier, Michel,Dias, Eric,Urban, Frank J.,Jasys, V. John,Kath, John C.,Kissel, William,Le, Tung,Li, Z. Jane,Negri, Joanna,Poss, Christopher S.,Tucker, John,Whritenour, David,Zandi, Kathleen
, p. 466 - 471 (2012/12/25)
Process development for the synthesis of 2-quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)-methyl]-2, 7-dihydroxy-7-methyloctyl] is described. An optimized and streamlined process starting from lactone 2 was developed: Lactone
Novel CCR1 antagonists with improved metabolic stability
Brown, Matthew F.,Avery, Mike,Brissette, William H.,Chang,Colizza, Kevin,Conklyn, Maryrose,DiRico, Amy P.,Gladue, Ronald P.,Kath, John C.,Krueger, Suzanne S.,Lira, Paul D.,Lillie, Brett M.,Lundquist, Greg D.,Mairs, Erin N.,McElroy, Eric B.,McGlynn, Molly A.,Paradis, Timothy J.,Poss, Christopher S.,Rossulek, Michelle I.,Shepard, Richard M.,Sims, Jeff,Strelevitz, Timothy J.,Truesdell, Susan,Tylaska, Laurie A.,Yoon, Kwansik,Zheng, Deye
, p. 2175 - 2179 (2007/10/03)
The synthesis, biological activity, and pharmacokinetic profile of novel CCR1 antagonists are described.
